Jazz Pharmaceuticals Expands Neuroscience Portfolio with Exclusive Licensing Agreement for SAN2355

SAN2355 is a subtype-selective activator of Kv7.2/Kv7.3 potassium channels, currently in preclinical development. This unique mechanism is validated for its efficacy in seizure suppression, differentiating it from existing non-selective Kv7-targeting compounds. Due to its selective action, SAN2355 has the potential to minimize the adverse effects commonly associated with off-target activation, positioning it as a best-in-class candidate in the treatment landscape for epilepsy.

Robert Iannone, M.D., M.S.C.E., Jazz Pharmaceuticals’ executive vice president and chief medical officer, expressed optimism about SAN2355’s potential, stating, “This transaction further expands our early-stage neuroscience pipeline and supports our commitment to developing novel approaches for people living with epilepsy and other neurologic conditions.”

Under the terms of the licensing agreement, Saniona will receive an upfront payment of $42.5 million. Additionally, the agreement includes a potential for Saniona to earn up to $192.5 million in development and regulatory milestones, with a specific milestone payment of $7.5 million upon the initiation of the first Phase 1 clinical study.

Saniona is also eligible for up to $800 million in commercial milestone payments based on the achievement of significant net sales thresholds. Furthermore, tiered royalties ranging from mid-single digits to low-double digits on net sales of any commercial products resulting from the development of SAN2355 will be provided to Saniona.

Thomas Feldthus, CEO of Saniona, emphasized the strategic nature of the collaboration, noting that it allows Saniona to advance several of its other valuable pipeline programs while leveraging Jazz’s leadership in epilepsy treatment. “Jazz's commitment to develop life-changing medicines for people with serious diseases aligns with our mission to improve outcomes for those affected by neurological and psychiatric disorders,” he remarked.

Jazz Pharmaceuticals is a global biopharmaceutical company dedicated to transforming the lives of patients through innovative therapies. With a diverse portfolio that includes treatments for sleep disorders and epilepsy, as well as a growing selection of cancer therapies, Jazz continues to focus on pioneering research and development in the fields of oncology and neuroscience. Headquartered in Dublin, Ireland, the company is committed to developing potentially life-changing medicines for patients worldwide.

Saniona is a clinical-stage biopharmaceutical company specializing in the development of innovative treatments for neurological and psychiatric disorders. The company boasts an internal pipeline that includes additional promising candidates for conditions such as epilepsy and major depressive disorder. Saniona has established strategic collaborations with leading pharmaceutical firms, including Jazz Pharmaceuticals, to enhance its development capabilities and expand treatment options for patients.

The collaboration between Jazz Pharmaceuticals and Saniona marks a significant advancement in the development of targeted therapies for epilepsy. With the promising profile of SAN2355 and the financial backing provided by this exclusive licensing agreement, both companies are well-positioned to make strides toward improving the treatment landscape for epilepsy and related neurological conditions. As they embark on this journey, the medical community and patients alike will be watching closely for developments in the clinical progression of SAN2355.